Patents by Inventor Jari Helin
Jari Helin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240000963Abstract: Hydrophilic linkers and their conjugates are disclosed.Type: ApplicationFiled: September 18, 2023Publication date: January 4, 2024Applicant: GLYKOS FINLAND OYInventors: Tero SATOMAA, Jari HELIN, Juhani SAARINEN
-
Patent number: 11793886Abstract: Hydrophilic linkers and their conjugates are disclosed.Type: GrantFiled: June 20, 2018Date of Patent: October 24, 2023Assignee: Glykos Finland OyInventors: Tero Satomaa, Jari Helin, Juhani Saarinen
-
Patent number: 11723983Abstract: The invention relates to a glycoprotein-toxic pay-load molecule conjugate, a toxic payload molecule-glycan conjugate, and a pharmaceutical composi-tion. The invention further relates to a method for preparing the glycoprotein-toxic payload molecule conjugate, the method for modulating growth of a cell population and a method of treating tu-mour cells.Type: GrantFiled: March 23, 2021Date of Patent: August 15, 2023Assignee: GLYKOS FINLAND OYInventors: Tero Satomaa, Jari Helin, Filip S. Ekholm
-
Publication number: 20230038373Abstract: A conjugate is disclosed. The conjugate may be represented by Formula I: [D-G-L]n-T Formula I wherein D is a payload molecule; O is an oxygen atom of said payload molecule; T is a targeting unit capable of binding a target molecule, cell and/or tissue; and n is at least 1.Type: ApplicationFiled: December 18, 2020Publication date: February 9, 2023Applicant: Glykos Biomedical OYInventors: Tero SATOMAA, Juhani SAARINEN, Jari HELIN, Olli AITIO, Henna PYNNÖNEN
-
Publication number: 20210252158Abstract: The invention relates to a glycoprotein-toxic pay-load molecule conjugate, a toxic payload molecule-glycan conjugate, and a pharmaceutical compos-ition. The invention further relates to a method for preparing the glycoprotein-toxic payload molecule conjugate, the method for modulating growth of a cell population and a method of treating tu-mour cells.Type: ApplicationFiled: March 23, 2021Publication date: August 19, 2021Applicant: GLYKOS FINLAND OYInventors: Tero SATOMAA, Jari HELIN, Filip S. EKHOLM
-
Publication number: 20210214510Abstract: A nanofibrillar cellulose hydrogel is disclosed. The nanofibrillar cellulose hydrogel may comprise azido-modified nanofibrillar cellulose having a substituent represented by the formula —O—(CH2)n—S(O)m-L1-N3, wherein n is in the range of 1 to 10; m is 0 or 1; and L1 is a linker; wherein the substituent is attached to a carbon of one or more glucosyl units of the azido-modified nanofibrillar cellulose, thus forming an ether bond to the carbon.Type: ApplicationFiled: May 23, 2019Publication date: July 15, 2021Inventors: Markus Nuopponen, Lauri Paasonen, Tero Satomaa, Olli Aitio, Jari Helin
-
Publication number: 20210106692Abstract: The present invention relates to a conjugate represented by the formula [D-L-Y—(CH2)n-]mP-T wherein T is a protein; P is a polymer selected from the group consisting of dextran, mannan, pullulan, hyaluronic acid, hydroxyethyl starch, chondroitin sulphate, heparin, heparin sulphate, polyalkylene glycol, Ficoll, polyvinyl alcohol, amylose, amylopectin, chitosan, cyclodextrin, pectin and carrageenan, or a derivative thereof; m is at least 1; n is in the range of 1 to 10; each Y is independently selected from the group consisting of S, NH and 1,2,3-triazolyl, wherein 1,2,3-triazolyl is optionally substituted; each L is independently absent or comprises a linker group covalently joining D and Y; and each D is a payload molecule.Type: ApplicationFiled: September 22, 2020Publication date: April 15, 2021Applicant: Glykos Finland OyInventors: Jari Helin, Juhani Saarinen, Filip S. Ekholm, Anne Leppanen
-
Publication number: 20210106689Abstract: A molecule comprising a saccharide bound via an O-glycosidic bond to a hydroxyl group of a toxic payload molecule is disclosed. An antibody-drug conjugate comprising an antibody covalently bound to a toxic payload molecule, optionally via a linker group, and a saccharide bound via an O-glycosidic bond to a hydroxyl group of the toxic payload molecule is further disclosed.Type: ApplicationFiled: November 4, 2020Publication date: April 15, 2021Applicant: Glykos Finland OyInventors: Jari Helin, Juhani Saarinen, Tero Satomaa, Filip S. Ekholm
-
Patent number: 10973920Abstract: A molecule comprising a saccharide bound via an O-glycosidic bond to a hydroxyl group of a toxic payload molecule is disclosed. An antibody-drug conjugate comprising an antibody covalently bound to a toxic payload molecule, optionally via a linker group, and a saccharide bound via an O-glycosidic bond to a hydroxyl group of the toxic payload molecule is further disclosed.Type: GrantFiled: June 26, 2015Date of Patent: April 13, 2021Assignee: GLYKOS FINLAND OYInventors: Jari Helin, Juhani Saarinen, Tero Satomaa, Filip S. Ekholm
-
Patent number: 10973922Abstract: The invention relates to a glycoprotein-toxic payload molecule conjugate, a toxic payload molecule-glycan conjugate, and a pharmaceutical composition. The invention further relates to a method for preparing the glycoprotein-toxic payload molecule conjugate, the method for modulating growth of a cell population and a method of treating tumour cells.Type: GrantFiled: September 14, 2017Date of Patent: April 13, 2021Assignee: Glykos Finland OYInventors: Tero Satomaa, Jari Helin, Filip S. Ekholm
-
Patent number: 10835606Abstract: The present invention relates to a conjugate comprising an anti-EGFR1 antibody or an EGFR binding fragment thereof and at least one dextran derivative, wherein the dextran derivative comprises at least one D-glucopyranosyl unit, wherein at least one carbon selected from carbon 2, 3 or 4 of the at least one D-glucopyranosyl unit is substituted by a substituent of the formula —O—(CH2)”—S—Bi2Hii2? wherein n is in the range of 3 to 10; and the dextran derivative is bound to the anti-EGFR antibody or an EGFR1 binding fragment thereof via a bond formed by a reaction between at least one aldehyde group formed by oxidative cleavage of a D-glucopyranosyl unit of the dextran derivative and an amino group of the anti-EGFR1 antibody or an EGFR1 binding fragment thereof.Type: GrantFiled: April 15, 2019Date of Patent: November 17, 2020Assignee: Tenboron OyInventors: Anne Leppanen, Filip S. Ekholm, Jari Helin, Hanna Salo, Anne Kanerva
-
Publication number: 20200323995Abstract: Hydrophilic linkers and their conjugates are disclosed.Type: ApplicationFiled: June 20, 2018Publication date: October 15, 2020Applicant: GLYKOS FINLAND OYInventors: Tero SATOMAA, Jari HELIN, Juhani SAARINEN
-
Patent number: 10449249Abstract: Objective of the present invention is to provide polysaccharides which modulate immune response, and which can be used as ingredients in edible products or pharmaceutical compositions. The present invention provides such polysaccharides obtained from the species Camellia sinensis, which comprise a rhamnogalacturonan-I core, and wherein the molar ratio of galacturonyl acid residues to rhamnosyl residues in the backbone of the polysaccharide is close to 1:1. The present invention also provides edible products or pharmaceutical compositions containing such polysaccharides, in order to modulate immune response.Type: GrantFiled: August 3, 2018Date of Patent: October 22, 2019Assignee: NUTRILEADS B.V.Inventors: Ruud Albers, Jari Helin, Werner Klaffke, Jean Hypolites Koek, Petronella Anna Kreijveld, Jari Natunen, Erwin Werner Tareilus, Richardus Paulus Anton Oranje
-
Publication number: 20190240330Abstract: The present invention relates to a conjugate comprising an anti-EGFR1 antibody or an EGFR binding fragment thereof and at least one dextran derivative, wherein the dextran derivative comprises at least one D-glucopyranosyl unit, wherein at least one carbon selected from carbon 2, 3 or 4 of the at least one D-glucopyranosyl unit is substituted by a substituent of the formula —O—(CH2)”—S—Bi2Hii2? wherein n is in the range of 3 to 10; and the dextran derivative is bound to the anti-EGFR antibody or an EGFR1 binding fragment thereof via a bond formed by a reaction between at least one aldehyde group formed by oxidative cleavage of a D-glucopyranosyl unit of the dextran derivative and an amino group of the anti-EGFR1 antibody or an EGFR1 binding fragment thereof.Type: ApplicationFiled: April 15, 2019Publication date: August 8, 2019Applicant: Tenboron OyInventors: Anne Leppanen, Filip S. Ekholm, Jari Helin, Hanna Salo, Anne Kanerva
-
Patent number: 10328149Abstract: The present invention relates to a conjugate comprising an anti-EGFR1 antibody or an EGFR binding fragment thereof and at least one dextran derivative, wherein the dextran derivative comprises at least one D-glucopyranosyl unit, wherein at least one carbon selected from carbon 2, 3 or 4 of the at least one D-glucopyranosyl unit is substituted by a substituent of the formula —O—(CH2)n—S—B12H112? wherein n is in the range of 3 to 10; and the dextran derivative is bound to the anti-EGFR antibody or an EGFR1 binding fragment thereof via a bond formed by a reaction between at least one aldehyde group formed by oxidative cleavage of a D-glucopyranosyl unit of the dextran derivative and an amino group of the anti-EGFR1 antibody or an EGFR1 binding fragment thereof.Type: GrantFiled: June 12, 2015Date of Patent: June 25, 2019Assignee: TENBORON OYInventors: Anne Leppanen, Filip S. Ekholm, Jari Helin, Hanna Salo, Anne Kanerva
-
Publication number: 20180339040Abstract: Objective of the present invention is to provide polysaccharides which modulate immune response, and which can be used as ingredients in edible products or pharmaceutical compositions. The present invention provides such polysaccharides obtained from the species Camellia sinensis, which comprise a rhamnogalacturonan-I core, and wherein the molar ratio of galacturonyl acid residues to rhamnosyl residues in the backbone of the polysaccharide is close to 1:1. The present invention also provides edible products or pharmaceutical compositions containing such polysaccharides, in order to modulate immune response.Type: ApplicationFiled: August 3, 2018Publication date: November 29, 2018Inventors: Ruud ALBERS, Jari HELIN, Werner KLAFFKE, Jean Hypolites KOEK, Petronella Anna KREIJVELD, Jari NATUNEN, Erwin Werner TAREILUS, Richardus Paulus Anton ORANJE
-
Patent number: 10098948Abstract: Objective of the present invention is to provide polysaccharides which modulate immune response, and which can be used as ingredients in edible products or pharmaceutical compositions. The present invention provides such polysaccharides obtained from the species Camellia sinensis, which comprise a rhamnogalacturonan-I core, and wherein the molar ratio of galacturonyl acid residues to rhamnosyl residues in the backbone of the polysaccharide is close to 1:1. The present invention also provides edible products or pharmaceutical compositions containing such polysaccharides, in order to modulate immune response.Type: GrantFiled: February 8, 2016Date of Patent: October 16, 2018Assignee: NUTRILEADS B.V.Inventors: Ruud Albers, Jari Helin, Werner Klaffke, Jean Hypolites Koek, Petronella Anna Kreijveld, Jari Natunen, Erwin Werner Tareilus, Richardus Paulus Anton Oranje
-
Publication number: 20180256732Abstract: The invention relates to a glycoprotein-toxic payload molecule conjugate, a toxic payload molecule-glycan conjugate, and a pharmaceutical composition. The invention further relates to a method for preparing the glycoprotein-toxic payload molecule conjugate, the method for modulating growth of a cell population and a method of treating tumour cells.Type: ApplicationFiled: September 14, 2017Publication date: September 13, 2018Applicant: GLYKOS FINLAND OYInventors: Tero SATOMAA, Jari HELIN, Filip S. EKHOLM
-
Publication number: 20180228906Abstract: A molecule comprising a saccharide bound via an O-glycosidic bond to a hydroxyl group of a toxic payload molecule is disclosed. An antibody-drug conjugate comprising an antibody covalently bound to a toxic payload molecule, optionally via a linker group, and a saccharide bound via an O-glycosidic bond to a hydroxyl group of the toxic payload molecule is further disclosed.Type: ApplicationFiled: June 26, 2015Publication date: August 16, 2018Applicant: Glykos Finland OyInventors: Jari Helin, Juhani Saarinen, Tero Satomaa, Filip S. Ekholm
-
Patent number: 9951148Abstract: The invention relates to a method for production of a preparation from a vegetable material, said preparation being enriched in a polysaccharide with a backbone comprising rhamnogalacturonan-I cores, said method comprising the steps: mixing the vegetable material with a polar alcoholic solvent; and separating a solid residue obtained in step a) from the solvent; and mixing the solid residue obtained in step b) with a buffered aqueous solution having a pH between 7 and 8. Also provided is a preparation containing rhamnogalacturonan-I pectins that can be obtained by this method and the use of such a preparation to modulate immune response.Type: GrantFiled: April 27, 2012Date of Patent: April 24, 2018Assignee: NutriLeads B.V.Inventors: Jari Helin, Jean Hypolites Koek